

JC JCWSCS 08 APR 2004

04/08/04 10:15 FAX 908 298 5405

SCHERING-PLOUGH

001

IPW

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP 1990
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO:	FAX NUMBER:
USPTO	(703) 746-9195
FROM:	PHONE NUMBER:
Palaiyur S. Kalyanaraman	(908) 298-5068
TOTAL NO. OF PAGES INCLUDING COVER	DATE
5	April 8, 2004

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashby Armstrong at (908) 298-4025.

NOTES/COMMENTS:


PLEASE HAND DELIVER

In re Application of: T. Guzi *et al.*
For Patent entitled: "Novel Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors"
Group Art Unit: 1614
Filed: 09/03/2003
Attorney Docket No.: OC01617K
Serial No.: 10/654,546

Dear Examiner McKenzie:

Transmitted herewith are:

- Certificate of Transmission under 37 CFR 1.8 – 1pg.
- Fax Cover Sheet – 1pg.
- Transmittal Letter – 1pg.
- Copy of Filing Receipt with corrections – 2pgs.



Palaiyur S. Kalyanaraman
Registered Representative
Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388

PAGE 1/5 * RCVD AT 4/8/2004 10:11:36 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-2/1 * DNIS:7469195 * CSID:908 298 5405 * DURATION (mm:ss):01:58

Attorney Docket No.: OC01617K

Application No.: 10/654,546

Filing Date: 09/03/2003

First Named Inventor: Timothy J. Guzi

PTO/SB/87 (08-03)


Approved for use through 07/31/2008. GMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-746-9195)

on 04/08/2004
Date


Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document(s) being transmitted:

Certificate of Transmission under 37 CFR 1.8 - 1pg.

Fax Cover Sheet - 1pg.

Transmittal Letter - 1pg.

Copy of Filing Receipt with Corrections - 2pgs.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT CASE NO. OC01617K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : Examiner: Dr. T. C. McKenzie
T. Guzi et al. : Group Art Unit: 1614
Serial No.: 10/654,546 : Date: April 8, 2004
Filing date: 09/03/2003
For: "Novel Pyrazolopyrimidines as
Cyclin Dependent Kinase Inhibitors" :

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attn: Office of the Initial Patent Examination's Filing Receipt Corrections
Fax: 703-746-9195

Correction of Filing Receipt

Sir:

The applicant has noted an error in the filing receipt for the above-captioned non-provisional patent application. Specifically, the number of total claims and the number of independent claims are marked erroneously. The correct numbers should be "Total claims 42" and "Independent claims 5". (The independent claims are claims 1, 27, 28, 29 and 30). Applicants are enclosing a copy of the Filing Receipt with the corrections marked thereon. Appropriate correction of the filing receipt is requested.

If there are any questions, the Office is invited to contact the undersigned.

April 8, 2004
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Tel.: (908) 298-5068
Fax: (908) 298-5388

Respectfully submitted,



Dr. Palaiyur S. Kalyanaraman
Attorney/Agent for Applicant(s)
Registration No.: 34,634



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE RECD	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/654,546 ✓	09/03/2003 ✓	1614	1212	OC01617K ✓			

44-42155-1390
CONFIRMATION NO. 3990

24265
 SCHERING-PLough CORPORATION
 PATENT DEPARTMENT (K-6-1, 1990)
 2000 GALLOPING HILL ROAD
 KENILWORTH, NJ 07033-0530

FILING RECEIPT



"OC000000011340186"

Date Mailed: 12/01/2003 ✓

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

✓ Timothy J. Guzi, Chatham, NJ;
 ✓ Kamil Paruch, Garwood, NJ;
 ✓ Michael P. Dwyer, Scotch Plains, NJ;
 ✓ Ronald J. Doll, Convent Station, NJ;
 ✓ Viyyoor M. Girijavallabhan, Parsippany, NJ;
 ✓ Alan Mallams, Hackettstown, NJ;
 ✓ Carmen S. Alvarez, Livingston, NJ;
 ✓ Kartik M. Keertikar, East Windsor, NJ;
 ✓ Zocelyn Rivera, Monmouth Junction, NJ;
 ✓ Tin-Yau Chan, Edison, NJ;
 ✓ Vincent Madison, Mountain Lakes, NJ;
 ✓ Thierry O. Fischmann, Scotch Plains, NJ;
 ✓ Lawrence W. Dillard, Skillman, NJ;
 ✓ Vinh D. Tran, Fountain Valley, CA;
 ✓ Zhen Min He, Princeton, NJ;
 ✓ Ray Anthony James, Bristol, PA;
 ✓ Haengsoon Park, Plainsboro, NJ;
 ✓ Vidyadhar M. Paradkar, Somerville, NJ;
 ✓ Douglas Walsh Hobbs, Yardley, PA;

**PATENT DEPARTMENT
RECEIVED**

DEC 05 2003

Computer Input	12-4-03
Date:	
PA:	Ray Anthony James, Bristol, PA
Attny:	
<input type="checkbox"/> FILE	<input type="checkbox"/> CHECK FILE

Assignment For Published Patent Application

✓ Schering Corporation;
 ✓ Pharmacopeia, Inc.;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/408,027 09/04/2002
and claims benefit of 60/421,959 10/29/2002

Foreign Applications**If Required, Foreign Filing License Granted: 11/21/2003****Projected Publication Date: To Be Determined - pending completion of Missing Parts****Non-Publication Request: No****Early Publication Request: No****Title**

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy